Ryvu Therapeutics

Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies addressing high value emerging targets in precision oncology. Ryvu Therapeutics was founded in 2007 (formerly known as Selvita) and currently employs 150 scientists, including 80 Ph.Ds. Our pipeline is built from internally-discovered candidates which make use of diverse therapeutic mechanisms, including programs directed at targets in the areas of transcriptional regulation, synthetic lethality, immuno-oncology and immunometabolism. Ryvu’s lead candidate, SEL120, is a selective CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, currently in Phase 1b study for the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome. SEL24/MEN1703 is a clinical stage program discovered and developed by Ryvu and licensed to the Menarini Group. SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor in Phase 1/2 clinical development for the treatment of acute myeloid leukemia. Additional programs include candidates directed at SMARCA2/BRM, adenosine A2A/A2B receptor targets and STING agonists. Ryvu technological expertise is validated by global partnerships with Merck KGaA, Menarini Group and Leukemia & Lymphoma Society. Since 2014, the company is listed on the Warsaw Stock Exchange under the ticker SLV. Ryvu Therapeutics is organized for highly efficient R&D driven by breakthrough science, aiming to realize full value potential for its shareholders, partners and employees.